X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1663) 1663
Publication (142) 142
Book Review (31) 31
Book Chapter (6) 6
Dissertation (5) 5
Conference Proceeding (4) 4
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1049) 1049
humans (986) 986
diabetes mellitus, type 2 - drug therapy (658) 658
glucose (623) 623
sodium-glucose transporter 2 - antagonists & inhibitors (601) 601
diabetes (582) 582
animals (549) 549
male (521) 521
type 2 diabetes (508) 508
hypoglycemic agents - therapeutic use (474) 474
endocrinology & metabolism (408) 408
dapagliflozin (382) 382
female (343) 343
double-blind (331) 331
sodium (331) 331
diabetes mellitus (325) 325
glucosides - therapeutic use (320) 320
pharmacology & pharmacy (314) 314
dextrose (309) 309
insulin (269) 269
sodium-glucose transporter 2 - metabolism (266) 266
middle aged (265) 265
empagliflozin (251) 251
canagliflozin (247) 247
hypoglycemic agents - pharmacology (246) 246
glucose - metabolism (244) 244
hyperglycemia (241) 241
sglt2 inhibitor (235) 235
hypoglycemic agents - adverse effects (232) 232
type 2 diabetes mellitus (229) 229
glycemic control (214) 214
benzhydryl compounds - therapeutic use (210) 210
rats (207) 207
treatment outcome (200) 200
glucosides - pharmacology (197) 197
type-2 diabetes-mellitus (185) 185
blood glucose - metabolism (183) 183
diabetes mellitus, type 2 - blood (180) 180
safety (180) 180
metformin (177) 177
aged (174) 174
adult (172) 172
hypoglycemic agents (172) 172
mellitus (172) 172
blood pressure (168) 168
mice (167) 167
sglt2 inhibitors (167) 167
analysis (165) 165
blood glucose - drug effects (165) 165
care and treatment (162) 162
risk factors (158) 158
physiology (157) 157
diabetes mellitus, type 2 - metabolism (155) 155
glucosides - adverse effects (155) 155
hypoglycemic agents - administration & dosage (153) 153
inadequate glycemic control (153) 153
research (145) 145
sodium-glucose transporter 1 - metabolism (144) 144
drug therapy (140) 140
rodents (138) 138
internal medicine (137) 137
sglt2 (136) 136
kidney - metabolism (135) 135
diabetes mellitus, type 2 - complications (132) 132
clinical trials (130) 130
efficacy (130) 130
kidney (130) 130
glucose metabolism (128) 128
body weight (120) 120
benzhydryl compounds - pharmacology (118) 118
metabolism (117) 117
blood-pressure (111) 111
cardiac & cardiovascular systems (111) 111
glucosides - administration & dosage (111) 111
inhibitors (111) 111
kidney - drug effects (109) 109
medicine, general & internal (107) 107
diabetes mellitus, type 2 - physiopathology (105) 105
drug therapy, combination (104) 104
insulin resistance (104) 104
review (104) 104
sodium-glucose transporter 2 inhibitors (103) 103
benzhydryl compounds - adverse effects (102) 102
expression (100) 100
medicine & public health (100) 100
heart failure (99) 99
mortality (99) 99
diabetes therapy (98) 98
health aspects (98) 98
sodium-glucose cotransporter 2 inhibitor (97) 97
abridged index medicus (96) 96
glycated hemoglobin a - metabolism (95) 95
kidneys (95) 95
glucose transporter (93) 93
placebo-controlled trial (93) 93
biochemistry & molecular biology (92) 92
double-blind method (92) 92
patients (92) 92
hypoglycemia (91) 91
sodium-glucose transporter 1 - antagonists & inhibitors (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1604) 1604
French (17) 17
German (11) 11
Korean (11) 11
Spanish (11) 11
Japanese (7) 7
Chinese (3) 3
Danish (2) 2
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2013, Volume 15, Issue 12, pp. 1154 - 1160
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e100777
Inhibition of sodium glucose cotransporter 2 (SGLT2) has been reported as a new therapeutic strategy for treating diabetes. However, the effect of SGLT2... 
OXIDATIVE STRESS | ACTIVATION | HYPERGLYCEMIA | SGLT2 INHIBITOR | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | RATS | COMPLICATIONS | MELLITUS | PANCREATIC-FUNCTION | RENAL INJURY | Inflammation - pathology | Oxidative Stress | Kidney Cortex - metabolism | Body Weight - drug effects | Diabetic Nephropathies - drug therapy | Male | Kidney Function Tests | Inflammation - metabolism | Kidney - metabolism | Glomerular Mesangium - metabolism | Glomerular Mesangium - drug effects | Homeostasis - drug effects | Kidney - physiopathology | Disease Models, Animal | Diabetic Nephropathies - pathology | Gene Expression | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Kidney - drug effects | Macrophages - pathology | Diabetic Nephropathies - metabolism | Cells, Cultured | Diabetic Nephropathies - genetics | Kidney Cortex - pathology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Glomerular Mesangium - pathology | Macrophages - metabolism | Animals | Insulin-Secreting Cells - drug effects | Kidney Tubules, Proximal - metabolism | Glucose - metabolism | Inflammation - genetics | Benzhydryl Compounds - pharmacology | Mice | Apoptosis | Oxidases | Type 2 diabetes | Blood sugar | Analysis | Body weight | Diabetic nephropathies | Hemoglobin | DNA polymerases | Gene expression | Health aspects | Oxidative stress | RNA-directed DNA polymerase | Syngeneic grafts | Homeostasis | Glucose | Macrophages | Blood | NAD(P)H oxidase | Biomedical materials | Hyperglycemia | Rodents | Biocompatibility | Blood pressure | Inhibition | Pancreas | Pharmaceutical sciences | Age | University graduates | Neurochemistry | Creatinine | Kidneys | Cytokines | Diabetes mellitus | Osteopontin | Inflammation | Dentistry | Metabolism | Medicine | Studies | Inhibitors | Nephropathy | Sodium | Monocyte chemoattractant protein | Fibrosis | Infiltration | Diabetes | Monocyte chemoattractant protein 1
Journal Article
Diabetes, ISSN 0012-1797, 04/2017, Volume 66, Issue 4, pp. 1030 - 1040
Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for heart failure. T2DM is associated with altered cardiac energy metabolism,... 
POSITRON-EMISSION-TOMOGRAPHY | BSCL2/SEIPIN-DEFICIENT MICE | MYOCARDIAL OXIDATIVE-METABOLISM | INSULIN-RESISTANCE | CARDIAC-HYPERTROPHY | ENDOCRINOLOGY & METABOLISM | PROTEIN O-GLCNACYLATION | GENERALIZED LIPODYSTROPHY | MITOCHONDRIAL DYSFUNCTION | SEIP CONGENITAL LIPODYSTROPHY | SMALL-ANIMAL PET | Ventricular Dysfunction, Left | Diabetes Mellitus, Type 2 - genetics | Positron-Emission Tomography | Diabetes Mellitus, Type 2 - metabolism | Heterotrimeric GTP-Binding Proteins - genetics | Hyperglycemia | Cardiomyopathy, Hypertrophic | Myocardium - metabolism | Glucosides - therapeutic use | Radiopharmaceuticals | Thiazolidinediones - pharmacology | Benzhydryl Compounds - therapeutic use | Disease Models, Animal | Ventricular Function - drug effects | Hypoglycemic Agents - therapeutic use | Glucosides - pharmacology | Echocardiography | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Heart - diagnostic imaging | Hypoglycemic Agents - pharmacology | Mice, Knockout | Lipodystrophy - genetics | Diabetic Cardiomyopathies | Magnetic Resonance Imaging | Animals | Heart - drug effects | Fluorodeoxyglucose F18 | Benzhydryl Compounds - pharmacology | Mice | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Heart failure | Prevention | Animal experimentation | Dapagliflozin | Dosage and administration | Research | Risk factors | Prescription drugs | Glucose | Diabetes | Sodium | Rodents
Journal Article